FHI-B:CA:TSX-CI Health Care Giants Covered Call ETF (CAD)

ETF | Others |

Last Closing

CAD 12.89

Change

+0.14 (+1.10)%

Market Cap

CAD 0.05B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEQT:CA iShares Core Equity Portfolio

+0.31 (+0.89%)

CAD 6.64B
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

+0.06 (+0.22%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

+0.01 (+0.02%)

CAD 5.91B
PHYS-U:CA Sprott Physical Gold Trust

+0.26 (+1.17%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

+0.26 (+0.69%)

CAD 4.54B
HXT-U:CA Global X S&P/TSX 60 Index ETF

+0.39 (+0.84%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

+0.29 (+1.10%)

CAD 3.78B
PSLV-U:CA Sprott Physical Silver Trust

+0.01 (+0.09%)

CAD 3.29B
ZMMK:CA BMO Money Market Fund ETF Seri..

-0.01 (-0.02%)

CAD 3.24B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.18 (-0.78%)

CAD 2.78B

ETFs Containing FHI-B:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.20% 81% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.20% 81% B- 74% C
Trailing 12 Months  
Capital Gain -0.39% 8% B- 19% F
Dividend Return 3.28% 62% D 49% F
Total Return 2.89% 11% F 19% F
Trailing 5 Years  
Capital Gain 13.57% 49% F 50% F
Dividend Return 33.83% 89% A- 89% A-
Total Return 47.39% 66% D+ 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.06% 55% F 47% F
Dividend Return 4.62% 55% F 43% F
Total Return 0.55% 72% C 30% F
Risk Return Profile  
Volatility (Standard Deviation) 4.95% 82% B 92% A
Risk Adjusted Return 93.20% 95% A 91% A-
Market Capitalization 0.05B 43% F 22% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.